Hogan Lovells assisted Recordati Group on the licensing agreements with Aegerion

Press releases | 6 February 2019

Hogan Lovells assisted Recordati Group on the licensing agreements with Aegerion for the exclusive marketing rights to the Juxtapid drug in Japan for a value of USD 30 million in addition to further payments conditional upon achievement of commercial targets and orphan drug royalties.

Juxtapid is a product indicated for the treatment of homozygous familial hypercholesterolemia and has been approved as an "orphan" product by the Ministry of Health, Labour and Welfare in Japan.

The Hogan Lovells team, under the supervision of the Milan corporate partner Francesco Stella, worked together with Recordati's internal legal team, led by general counsel Daria Ghidoni. The Hogan Lovells team in Tokyo was led by IP partner Dr. Frederick Ch'en, while Giuseppe Colangelo is the in-house lawyer of Recordati who followed the transaction.

Aegerion was assisted by Goodwin Procter LLP.